Patents Assigned to ENLIVEX THERAPEUTICS R&D LTD
  • Publication number: 20230089828
    Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing SARS-CoV-2 vims infection in a subject in need, including methods of extending of the survival of a subject suffering from COVID-19, and reduction of organ dysfunction or failure due to COVID-19 or associated symptoms. Methods of treating or preventing COVID-19 in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying COVID-19 and symptoms thereof. Further, anti-inflammatory cytokine release may be increased. In certain instances, compositions may include additional agents.
    Type: Application
    Filed: February 21, 2021
    Publication date: March 23, 2023
    Applicant: ENLIVEX THERAPEUTICS R&D LTD
    Inventors: Shai NOVIK, Dror MEVORACH
  • Patent number: 11596652
    Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 7, 2023
    Assignee: ENLIVEX THERAPEUTICS R&D LTD
    Inventors: Shai Novik, Dror Mevorach
  • Patent number: 11497767
    Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: November 15, 2022
    Assignee: ENLIVEX THERAPEUTICS R&D LTD
    Inventors: Shai Novik, Dror Mevorach